BeiGene
BGNE
#984
Rank
โ‚น1.695 T
Marketcap
โ‚น15,201
Share price
1.55%
Change (1 day)
0.32%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : โ‚น494.99 Billion

According to BeiGene 's latest financial reports the company's total assets are โ‚น494.99 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚น483.28 B-8.45%
2022-12-31โ‚น527.88 B-16.91%
2021-12-31โ‚น635.30 B55.1%
2020-12-31โ‚น409.60 B256.26%
2019-12-31โ‚น114.97 B-26.91%
2018-12-31โ‚น157.30 B135.42%
2017-12-31โ‚น66.81 B142.3%
2016-12-31โ‚น27.57 B255.39%
2015-12-31โ‚น7.75 B128.33%
2014-12-31โ‚น3.39 B366.25%
2013-12-31โ‚น0.72 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚น1.54 B-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น191.52 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA